Despite strong opposition from former White House Press Secretary Sean Spicer and Attorney General Jeff Sessions, and the overall limitations imposed by federal illegality in the U.S., 2017 is shaping up to be a great year for the North American cannabis industry.
Tag Archives: investors
MIAMI, Oct. 11, 2017 /Weed Wire/ – Amazonas Florestal Ltd. (www.azflusa.com) (OTC PINK: AZFL), a natural resources company dedicated to innovative, sustainable forest management, industrial CBD hemp and the certification and sales of carbon credits wants to update shareholders and investors that the Company will resume operations this week in order to complete harvesting process for the first 100 acre plantation between this week and the next.
The stock of MedReleaf Corp. has recently outperformed those of other top marijuana stock players in Canada, and there could be further price gains going forward after the recently listed cannabis firm has found its footing and stopped the earlier quarterly revenue declines.
Legal pot sales rose a stunning 34% in 2016 to $6.7 billion across North America, according to Arcview Market Research. But with growth this rapid, there’s bound to be more than a few marijuana stock investments that will be left behind.
Canada’s biggest medical cannabis producers are seeing their stock prices rise after the federal government announced a plan to levy a one dollar per gram tax on recreational marijuana sales.
Marijuana companies should be careful in overselling how much growth will be achieved or what the prospects will look like for the industry. There is a recent example that cannabis investors would be wise to review, and that’s what happened with Freshii Inc..
After the company announced it will tap investors for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix (NASDAQ: ZGNX) are rallying 10% at 2 p.m. EDT today.
Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel met the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities in adolescents and children.
Marijuana stock investors are going to have to keep their eyes on the following two critical data points for each and every marijuana stock they’re considering buying, or that they already own.
New Brunswick recently announced how the province will manage the sale and distribution of marijuana. New Brunswick has also signed deals with Canopy Growth Corp. (TSX:WEED) and another company listed on the venture exchange.
PALM BEACH, Fla., Sept. 15, 2017 /Weed Wire/ — More than 100 high net-worth investors from around the world will gather in Palm Beach at the Arcview Investor Forum next week to consider opportunities from dozens of promising cannabis companies in a “Shark Tank” like format.
The Ontario government announced September 8 that the LCBO will oversee the retail sale of cannabis in Ontario through standalone stores and an e-commerce site.
Almost three months after the initial public offering (IPO) of MedReleaf Corp. (TSX:LEAF), shares have yet to do much in either direction. The company, which came to market in what was then described as a “botched IPO,” fell quickly out of the gate from its IPO price.
Arizona’s attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
Undoubtedly, a reversal in the federal government’s laxness on pot would be terrible news for marijuana stock investors, but not every last company would be decimated. One marijuana stock could still thrive, even with Jeff Sessions waving the metaphorical sword at the pot industry: Scotts Miracle-Gro.
With prices for many major Canadian cannabis stocks such as Canopy Growth Corp., Aphria Inc., and Aurora Cannabis Inc. trading sideways over the past few months, investors are now wondering which direction stocks will move from here, and what the long-term play with this industry is overall.
Further to the ASX announcement dated 29 August 2017 title ‘Priority Share Offer for CannPal Animal Therapeutics Ltd IPO Shares’, the Board of Zelda Therapeutics Ltd wishes to clarify the Priority Offer Record Date.
Canopy Growth Corp. (TSX:WEED) was the first cannabis stock to the market and quickly captured the attention of traders and risk-taking growth investors alike. As a result, shares of Canopy skyrocketed 300% in a span of just a few months last year.
PALM BEACH, Fla., Aug. 30, 2017 /Weed Wire/ — More than 200 high-net worth investors from around the world, eager to invest in the fastest growing industry in America will gather at the Eau Palm Beach Resort & Spa for a two day “Shark Tank”-like pitch forum on Tuesday, September 19th and Wednesday, September 20th, hosted exclusively for members of The Arcview Investor Network.
It seems as though news of recalls related to specific batches of bad marijuana from licensed Canadian producers has been coming in more frequently than marijuana investors and consumers would like to see.
Whereas most weed businesses are working harder than ever to increase their grow capacity, Cronos Group is a company that’s trying to work smarter. Based in Canada, Cronos Group is an investment firm that primarily invests in Canadian-based pot companies involved in Canada’s medical-marijuana industry.
Medical cannabis companies and investors are calling on Gov. Greg Abbott’s office and the Department of Public Safety to approve more dispensary licenses beyond the three given provisional approval in May.
Any move by the Toronto Stock Exchange owner to stop settling trades for marijuana companies with U.S. operations would undermine the market’s regulatory system, according to one Canadian pot company.
There has been a lot of news in the marijuana industry this year. The medical marijuana industry exploded, and many new companies came to market in a frenzy, which reminded investors of the exciting technology bubble.
TMX Group Ltd. (TSX:X), the operator of the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV), has reportedly been speaking with regulators to figure out what will happen to Canadian marijuana producers with assets in the U.S.
Today, investors are licking their chops over the prospect of a “green rush” when recreational retailers and weed makers are allowed to open for business Jan. 1.
GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
If you look around, chances are you won’t find many marijuana stocks struggling. But there’s always an outlier — and for the marijuana industry that’s drugmaker Insys Therapeutics.
TMX Group Ltd’s CEO on Thursday brushed off signs that the grip of Canada’s dominant stock exchange operator on overall trading volumes was slipping, saying recent market share losses were mostly due to its rejection of certain listings.
When GW Pharmaceuticals announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. However, it wasn’t any of the numbers in the update that caused this decline. Instead, one word caused investors’ disappointment.
For many weed stocks, the summer of 2017 hasn’t been what you’d call a scorcher. However, three marijuana stocks have sizzled this summer.
If just a single clinical trial works in favor of Cara Therapeutics, it could regain everything it’s recently lost and possibly hit a $1 billion market cap.
Identifying companies in great financial health is important when investing in an industry like marijuana. That being said, the Canadian marijuana stocks on our list all have current ratios of at least 10x, and debt to equity ratios under 20%.
In mid-June home lawn and fertilizer care specialist The Scotts Miracle-Gro Company (NYSE:SMG) lowered its full-year fiscal 2017 outlook, citing a more than 10% drop in mass retail sales compared to the year-to-date checkpoint from the previous year. That was caused by challenging weather this spring in core markets across the United States.
The Creso Pharma Ltd (ASX: CPH) share price has been amongst the biggest movers on the market this morning. This morning the company revealed that it plans to expand into the Canadian market.
WASHINGTON, July 27, 2017 /Weed Wire/ — New Frontier Data (www.newfrontierdata.com), an independent, technology-driven analytics company specializing in the cannabis industry, announced today the appointment of Gary Allen as chief operating officer, capping a first half of 2017 filled with rapid advancement and innovation.
Over the trailing-12-month period through July 15, the average marijuana stock with a market cap in excess of $200 million — a dozen stocks in total, which excluded MedReleaf because it just went public a month ago — was up by 332%.
DENVER, July 24, 2017 /Weed Wire/ — MassRoots, Inc. (OTCQB:MSRT), one of the leading technology and compliance platforms for the cannabis industry, is pleased to announce it has closed a $1,217,000 private placement of common stock and warrants, as detailed in MassRoots’ Current Report on Form 8-K filed on July 24, 2017 with the U.S. Securities and Exchange Commission.
In total, four marijuana stocks jumped higher by at least 10% last week. Let’s take a brief look at some of these moves.
Few stocks have skyrocketed like Axim Biotechnologies. Last year, Axim ranked not only as the best marijuana stock in terms of overall performance, but also took the top spot among all biotech stocks.
Here, CEOs and cannabis executives share their advice on using social media to reach customers, suppliers, investors and the press.
Well, we have news for Canadian marijuana stock investors: There’s a new threat on the horizon, at least for our neighbors to the north.
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.
Only 51 authorized licenses have been given to suppliers of medical marijuana in Canada. Canopy Growth Corporation holds four of them.
SAN FRANCISCO, July 12, 2017 /Weed Wire/ — Canna Angels LLC, a leading angel investment consortium focused on opportunities within the cannabis industry, today announced that RET. California State Senator Joe Dunn and Dr. Daniele Piomelli, PhD, Pharm.D., will be featured guests at the Canna Angels July 19 Founders Showcase.
On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.
There have been two interesting developments with marijuana producers Aurora Cannabis Inc. (TSXV:ACB) and Aphria Inc. (TSX:APH).
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
The results for Canopy Growth’s stock have been terrific so far, yielding a return of over 152% since inception. The stock has been performing well despite lacklustre results and frequent losses.